Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Molecules ; 28(13)2023 Jun 21.
Article in English | MEDLINE | ID: mdl-37446563

ABSTRACT

BACKGROUND: Benign prostatic hyperplasia (BPH) is a progressive urological disease occurring in middle-aged and elderly men, which can be characterized by the non-malignant overgrowth of stromal and epithelial cells in the transition zone of the prostate. Previous studies have demonstrated that lycopene can inhibit proliferation, while curcumin can strongly inhibit inflammation. This study aims to determine the inhibitory effect of the combination of lycopene and curcumin on BPH. METHOD: To induce BPH models in vitro and in vivo, the BPH-1 cell line and Sprague Dawley (SD) rats were used, respectively. Rats were divided into six groups and treated daily with a vehicle, lycopene (12.5 mg/kg), curcumin (2.4 mg/kg), a combination of lycopene and curcumin (12.5 mg/kg + 2.4 mg/kg) or finasteride (5 mg/kg). Histologic sections were examined via hematoxylin and eosin (H&E) staining and immunohistochemistry. Hormone and inflammatory indicators were detected via ELISA. Network pharmacology analysis was used to fully predict the therapeutic mechanism of the combination of lycopene and curcumin on BPH. RESULTS: Combination treatment significantly attenuated prostate hyperplasia, alleviated BPH pathological features and decreased the expression of Ki-67 in rats. The upregulation of the expression of testosterone, dihydrotestosterone (DHT), 5α-reductase, estradiol (E2) and prostate-specific antigen (PSA) in BPH rats was significantly blocked by the combination treatment. The expression levels of inflammatory factors including interleukin (IL)-1ß, IL-6 and tumor necrosis factor (TNF)-α were strongly inhibited by the combination treatment. From the network pharmacology analysis, it was found that the main targets for inhibiting BPH are AKT1, TNF, EGFR, STAT3 and PTGS2, which are enriched in pathways in cancer. CONCLUSION: The lycopene and curcumin combination is a potential and more effective agent to prevent or treat BPH.


Subject(s)
Curcumin , Prostatic Hyperplasia , Testosterone Propionate , Male , Humans , Rats , Animals , Prostatic Hyperplasia/chemically induced , Prostatic Hyperplasia/drug therapy , Prostatic Hyperplasia/metabolism , Testosterone Propionate/adverse effects , Rats, Sprague-Dawley , Lycopene/pharmacology , Lycopene/therapeutic use , Curcumin/pharmacology , Curcumin/therapeutic use , Propionates/pharmacology , Plant Extracts/pharmacology , Testosterone/metabolism , Inflammation/drug therapy , Cell Proliferation
2.
Inflammopharmacology ; 31(4): 2121-2131, 2023 Aug.
Article in English | MEDLINE | ID: mdl-36881348

ABSTRACT

Benign prostatic hyperplasia (BPH) is a non-malignant disease of the prostate characterized by uncontrolled proliferation of the prostate gland. Inflammation and oxidative stress have been reported to play a role in the development of BPH. Kolaviron, a bioflavonoid complex of Garcinia kola seed, has been shown to possess anti-inflammatory effect. In this study, we investigated the effect of Kolaviron on testosterone propionate (TP)-induced BPH in rats. Fifty male rats were assigned in 5 groups. Groups 1 and 2 were orally exposed to corn oil (2 ml/kg) and Kolaviron (200 mg/kg/day, p.o) for 28 days. Group 3 rats received TP (3 mg/kg/day, s.c) for 14 days while Groups 4 and 6 were treated with Kolaviron (200 mg/kg/day, p.o) and Finasteride (5 mg/kg/day, p.o), respectively, for 14 days prior to TP (3 mg/kg, s.c) co-exposure for the remaining 14 days. Administration of Kolaviron to TP-treated rats reverted histological alteration and significantly decreased prostate weight, prostate index, 5α-reductase, dihydrotestosterone, androgen receptor expression, tumor necrosis factor α, interleukin-1ß, cyclooxygenase-2, prostaglandin E2, 5-lipoxygenase leukotriene B4, inducible nitric oxide synthase and nitric oxide concentration. In addition, Kolaviron alleviated TP-induced oxidative stress and reduced the expression of Ki-67, VEGF, and FGF to almost control levels. Furthermore, Kolaviron promoted apoptosis in TP-treated rats through downregulation of BCL-2 and upregulation of P53 and Caspase 3 expressions. Overall, Kolaviron prevented BPH via regulation of androgen/androgen receptor signaling, anti-oxidative and anti-inflammatory mechanisms.


Subject(s)
Prostatic Hyperplasia , Testosterone Propionate , Humans , Rats , Male , Animals , Prostatic Hyperplasia/chemically induced , Prostatic Hyperplasia/drug therapy , Prostatic Hyperplasia/metabolism , Testosterone Propionate/adverse effects , Testosterone Propionate/metabolism , Prostate/metabolism , Prostate/pathology , Receptors, Androgen/metabolism , Testosterone/adverse effects , Testosterone/metabolism , Hyperplasia/metabolism , Hyperplasia/pathology , Rats, Sprague-Dawley , Plant Extracts/pharmacology , Flavonoids/pharmacology , Apoptosis
3.
Nutrients ; 15(4)2023 Feb 05.
Article in English | MEDLINE | ID: mdl-36839177

ABSTRACT

Benign prostatic hyperplasia (BPH) is the most common condition in elderly men that is characterized by an increase in the size of the prostate gland. Cinnamomum cassia and Rosa laevigata have been reported to treat the symptoms associated with BPH. The aim of this study was to evaluate the effects of HT080, an herbal extract of C. cassia and R. laevigata, on a testosterone propionate (TP)-induced BPH rat model. The rats received a daily subcutaneous injection of TP (3 mg/kg) for 4 weeks to induce BPH. Rats were divided into four groups: group 1 (sham), group 2 (BPH, TP alone), group 3 (Fina, TP + finasteride 1 mg/kg/day), and group 4 (HT080, TP + HT080 200 mg/kg/day). At the end of the experiment, all rats were sacrificed, and their prostate glands were removed, weighed, and subjected to histopathological examination and western blot analyses. Serum testosterone and dihydrotestosterone (DHT) levels were determined. In addition, serum alanine and aspartate aminotransferase levels were measured to evaluate the toxicity in the liver. The Hershberger bioassay was also conducted to investigate the effects of HT080 on androgenic and antiandrogenic activities. In the BPH model, the prostate weight, prostate index, prostate epithelial thickness, and serum testosterone and DHT levels in the HT080 group were significantly reduced compared to the BPH group. Histological studies showed that HT080 reduced prostatic hyperplasia. The protein expression of androgen receptor from the HT080 group was significantly reduced in comparison with the BPH group (p < 0.05). HT080 also induced apoptosis by regulating Bcl-2 and Bax expression. In addition, HT080 showed no toxicity in the liver and did not exhibit androgenic and antiandrogenic activities. Our finding revealed that HT080 can be a potential candidate for the treatment of BPH by regulating androgen receptor signaling and apoptosis.


Subject(s)
Cinnamomum aromaticum , Prostatic Hyperplasia , Rosa , Testosterone Propionate , Male , Humans , Rats , Animals , Prostatic Hyperplasia/chemically induced , Receptors, Androgen/metabolism , Rats, Sprague-Dawley , Plant Extracts/pharmacology , Testosterone Propionate/adverse effects , Androgens , Apoptosis , Testosterone
4.
Food Funct ; 13(19): 10235-10247, 2022 Oct 03.
Article in English | MEDLINE | ID: mdl-36124918

ABSTRACT

Centella asiatica (L.) Urban (C. asiatica) is a traditional herbal medicine that has been used for wound healing and anti-inflammation since ancient times. Various biological effects of C. asiatica ethanolic extract (CAE) were previously reported. However, in our previous study, C. asiatica aqueous extract (CAA) exhibited higher inhibitory activity on benign prostatic hyperplasia (BPH) than CAE. Therefore, the aim of this study was to investigate the effect of CAA on BPH, and elucidate the inhibitory mechanism through in vitro and in vivo experiments as well as metabolite analysis of CAA. A BPH rat model was induced by daily subcutaneous injection of testosterone propionate (TP, 3 mg kg-1) dissolved in corn oil for 4 weeks after castration. The experimental group, the CAA treatment group, was orally administered CAA (100 mg kg-1) for 4 weeks while inducing prostatic hyperplasia. Saw palmetto extract (Saw, 100 mg kg-1) and Finasteride (Fi, 1 mg kg-1) were used as positive controls and were administered orally for 4 weeks. CAA significantly inhibited androgen receptor signaling related factors overexpressed by dihydrotestosterone (DHT) treatment in prostate cell lines. Afterwards, the testosterone-induced BPH model was used to verify the alleviation efficacy of CAA in prostatic hyperplasia. Prostate size and the thickness of the prostate tissue epithelium were significantly decreased in the group treated with CAA compared to those in the BPH group. The results of protein expression in the prostate tissue confirmed that CAA inhibited androgen receptor signaling in BPH and decreased the expression of growth factors. Moreover, CAA suppressed the expression of the PI3K/Akt pathway and cell proliferation-related factors compared to the BPH group. Taken together, these results indicate that CAA improves the inhibitory efficacy of BPH by inhibiting the androgen receptor and PI3K/Akt pathways, suggesting that CAA may be a promising candidate for biopharmaceutical formulations of BPH.


Subject(s)
Centella , Prostatic Hyperplasia , Testosterone Propionate , Animals , Centella/metabolism , Corn Oil , Dihydrotestosterone/adverse effects , Finasteride/adverse effects , Humans , Male , Phosphatidylinositol 3-Kinases/genetics , Phosphatidylinositol 3-Kinases/metabolism , Plant Extracts , Prostate , Prostatic Hyperplasia/drug therapy , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Androgen/genetics , Receptors, Androgen/metabolism , Signal Transduction , Testosterone/metabolism , Testosterone Propionate/adverse effects , Triterpenes
5.
Cell Death Dis ; 13(6): 554, 2022 06 17.
Article in English | MEDLINE | ID: mdl-35715415

ABSTRACT

Benign prostate hyperplasia (BPH) is an age-related disease in men characterized by the growth of prostate cells and hyperproliferation of prostate tissue. This condition is closely related to chronic inflammation. In this study, we highlight the therapeutic efficacy of ellagic acid (EA) for BPH by focusing on the AR signaling axis and STAT3. To investigate the effect of EA on BPH, we used EA, a phytochemical abundant in fruits and vegetables, to treat testosterone propionate (TP)-induced BPH rats and RWPE-1 human prostate epithelial cells. The EA treatment reduced prostate weight, prostate epithelial thickness, and serum DHT levels in the TP-induced BPH rat model. In addition, EA improved testicular injury by increasing antioxidant enzymes in testis of the BPH rats. EA reduced the protein levels of AR, 5AR2, and PSA. It also induced apoptosis by regulating Bax, Bcl_xL, cytochrome c, caspase 9, and caspase 3 with increasing mitochondrial dynamics. Furthermore, EA reduced the expression of IL-6, TNF-α, and NF-κB, as well as phosphorylation of STAT3 and IκBα. These findings were also confirmed in TP-treated RWPE-1 cells. Overall, our data provide evidence of the role of EA in improving BPH through inhibition of AR and the STAT3 pathway.


Subject(s)
Prostatic Hyperplasia , Testosterone Propionate , Androgens/pharmacology , Animals , Ellagic Acid/adverse effects , Humans , Hyperplasia/pathology , Male , Plant Extracts/pharmacology , Prostate/metabolism , Prostatic Hyperplasia/chemically induced , Prostatic Hyperplasia/drug therapy , Prostatic Hyperplasia/metabolism , Rats , Rats, Sprague-Dawley , STAT3 Transcription Factor/metabolism , Testosterone Propionate/adverse effects
6.
PLoS One ; 15(8): e0236879, 2020.
Article in English | MEDLINE | ID: mdl-32790676

ABSTRACT

Benign prostatic hyperplasia (BPH) is a progressive pathological condition associated with proliferation of prostatic tissues, prostate enlargement, and lower-urinary tract symptoms. However, the mechanism underlying the pathogenesis of BPH is unclear. The aim of this study was to investigate the protective effects of a combination of Stauntonia hexaphylla and Cornus officinalis (SC extract) on a testosterone propionate (TP)-induced BPH model. The effect of SC extract was examined in a TP-induced human prostate adenocarcinoma cell line. Male Sprague-Dawley rats were randomly divided into 5 groups (n = 6) for in vivo experiments. To induce BPH, all rats, except those in the control group, were administered daily with subcutaneous injections of TP (5 mg/kg) and orally treated with appropriate phosphate buffered saline/drugs (finasteride/saw palmetto/SC extract) for 4 consecutive weeks. SC extract significantly downregulated the androgen receptor (AR), prostate specific antigen (PSA), and 5α-reductase type 2 in TP-induced BPH in vitro. In in vivo experiments, SC extract significantly reduced prostate weight, size, serum testosterone, and dihydrotestosterone (DHT) levels. Histologically, SC extract markedly recovered TP-induced abnormalities and reduced prostatic hyperplasia, thereby improving the histo-architecture of TP-induced BPH rats. SC extract also significantly downregulated AR and PSA expression, as assayed using immunoblotting. Immunostaining revealed that SC extract markedly reduced the 5α-reductase type 2 and significantly downregulated the expression of proliferating cell nuclear antigen. In addition, immunoblotting of B-cell lymphoma 2 (Bcl-2) family proteins indicated that SC extract significantly downregulated anti-apoptotic Bcl-2 and markedly upregulated pro-apoptotic B cell lymphoma-associated X (Bax) expression. Furthermore, SC treatment significantly decreased the Bcl-2/Bax ratio, indicating induced prostate cell apoptosis in TP-induced BPH rats. Thus, our findings demonstrated that SC extract protects against BPH by inhibiting 5α-reductase type 2 and inducing prostate cell apoptosis. Therefore, SC extract might be useful in the clinical treatment of BPH.


Subject(s)
Apoptosis/drug effects , Cholestenone 5 alpha-Reductase/chemistry , Plant Extracts/pharmacology , Prostatic Hyperplasia/prevention & control , Protective Agents/therapeutic use , 5-alpha Reductase Inhibitors/chemistry , 5-alpha Reductase Inhibitors/pharmacology , 5-alpha Reductase Inhibitors/therapeutic use , Animals , Cell Line, Tumor , Cell Proliferation/drug effects , Cholestenone 5 alpha-Reductase/metabolism , Cornus/chemistry , Cornus/metabolism , Down-Regulation/drug effects , Humans , Male , Plant Extracts/chemistry , Plant Extracts/therapeutic use , Plant Leaves/chemistry , Plant Leaves/metabolism , Prostate-Specific Antigen/blood , Prostatic Hyperplasia/etiology , Protective Agents/pharmacology , Proto-Oncogene Proteins c-bcl-2/metabolism , Ranunculales/chemistry , Ranunculales/metabolism , Rats , Rats, Sprague-Dawley , Testosterone Propionate/adverse effects
7.
J Nat Prod ; 83(4): 1183-1189, 2020 04 24.
Article in English | MEDLINE | ID: mdl-32191471

ABSTRACT

Oleanolic acid (OA) is a natural, biologically active pentacyclic triterpenoid found in Cornus officinalis. Although C. officinalis and OA have antiproliferative actions, the effects and mechanisms of OA in benign prostatic hyperplasia (BPH) are unclear. We examined the effect of OA in an animal model of testosterone-induced BPH. Male rats were injected with testosterone propionate with or without OA. The inhibitory effect of OA on BPH-1 cells was determined in vitro. Rats with BPH exhibited outstanding BPH symptoms, including prostatic enlargement, upregulated dihydrotestosterone and 5α-reductase 2 levels, and histological changes. Compared with the BPH group, the OA group showed fewer pathological alterations and regular androgen events. OA inhibited prostate cell proliferation by downregulating the expression of proliferating cell nuclear antigen (PCNA) and cell cycle markers in BPH-induced animals. This indicated that OA has superior therapeutic effect in the BPH animal model than finasteride. In vitro studies demonstrated upregulation of PCNA and cell cycle proteins, whereas OA clearly reduced this upregulation. Thus, OA may inhibit the development of BPH by targeting cell cycle progression markers. These suggest that OA is a potential agent for BPH treatment.


Subject(s)
Oleanolic Acid/pharmacology , Proliferating Cell Nuclear Antigen/therapeutic use , Prostatic Hyperplasia/drug therapy , Testosterone/chemistry , Animals , Cell Cycle/drug effects , Cell Proliferation/drug effects , Down-Regulation/drug effects , Humans , Male , Molecular Structure , Oleanolic Acid/chemistry , Proliferating Cell Nuclear Antigen/metabolism , Proliferating Cell Nuclear Antigen/pharmacology , Prostatic Hyperplasia/pathology , Rats , Testosterone/metabolism , Testosterone Propionate/adverse effects
8.
Probl Endokrinol (Mosk) ; 65(1): 19-30, 2019 05 14.
Article in Russian | MEDLINE | ID: mdl-31091047

ABSTRACT

BACKGROUND: Anabolic androgenic steroids (AASs) are often used by individuals engaged in physical recreational activity. AASs inhibit the hypothalamus-pituitary-gonad axis and can cause erectile dysfunction and reduced fertility. There is no data on the use of AASs in this category of people in the Russian Federation; therefore, a study exploring the rate and patterns of using steroids for non-medical purposes is topical. Aim - of this study was to investigate the rate and patterns of using AASs in males attending gyms in Saint Petersburg. MATERIAL AND METHODS: We used individual anonymous postal survey of males attending gyms. We analyzed demographic and anthropometric data, information on the use of AASs, awareness of their side effects, used agents, patterns and duration of their use, and rehabilitation therapy. RESULTS: Out of 1,815 sent questionnaires, we received back 762 ones. The criteria were met by 550 questionnaires. The mean age was 29.3±7.4 years. The use of AASs was reported by 30.4% of respondents. The main AAS (74.3%) consumers were males aged 22 to 35 years. The most popular drug was Testosterone Propionate (51.5%); the drug was often combined with Oxandrolone (19.7%). In 70.6% of cases, drugs were administered by injection or injection combined with tablet intake. The injectable testosterone dose ranged from 500 to 2,000 mg/week and above. The most common dose was 1,000 mg/week (23.9%). AAS administration for more than 1 year was reported in 16.1% of males. Anastrozole (55%), hCG (51.3%), Clomiphene (41.3%), and Tamoxifen (30.5%) were used during the recovery period. The main source of information on AASs, doses, and dosage patterns was the Internet (48.7%). A negative attitude towards AASs was found in 17.3% of respondents. The desire to receive qualified information about AASs and their impact on health was reported by 54.8% of the surveyed respondents. CONCLUSION: Almost every fourth gym visitor has experience in using AASs. These are males of an optimal reproductive age. The common pattern of using AASs is an aggressive steroid course followed by a recovery period. The list of used drugs and their doses indicate a significant pharmacological intervention and a high risk to health.


Subject(s)
Anabolic Agents/administration & dosage , Androgens/administration & dosage , Athletes/statistics & numerical data , Drug Utilization/statistics & numerical data , Exercise , Oxandrolone/administration & dosage , Testosterone Propionate/administration & dosage , Adult , Anabolic Agents/adverse effects , Androgens/adverse effects , Athletes/psychology , Awareness , Drug Administration Schedule , Health Knowledge, Attitudes, Practice , Humans , Male , Oxandrolone/adverse effects , Russia , Self Administration/statistics & numerical data , Self Medication/statistics & numerical data , Surveys and Questionnaires , Testosterone Propionate/adverse effects
9.
Nutrients ; 10(12)2018 Dec 07.
Article in English | MEDLINE | ID: mdl-30544543

ABSTRACT

Benign prostatic hyperplasia (BPH) is a common disease in the elderly male population throughout the world. Among other factors, androgen dysregulation has been known to play major roles in its pathogenesis. HX109 is a botanical formulation prepared from a mixture of Taraxacum officinale, Cuscuta australis, and Nelumbo nucifera, which have traditionally been used-usually along with other plants-to treat urinary diseases. An ethanol extract was prepared from a mixture of these three plants, and its quality was controlled through cell-based bioassays and by quantification of several marker compounds by high-performance liquid chromatography (HPLC). In the testosterone propionate (TP)-induced prostate hyperplasia rat model, oral administration of HX109 ameliorated prostate enlargement and histological changes induced by TP. In LNCaP cells, a human prostate epithelial cell line, HX109 repressed AR-mediated cell proliferation and the induction of androgen receptor (AR) target genes at the transcriptional level without affecting the translocation or expression of AR. Such effects of HX109 on AR signaling were mediated through the control of activating transcriptional factor 3 (ATF3) expression, phosphorylation of calcium/calmodulin-dependent protein kinase kinase ß (CaMKKß), and increases in intracellular calcium, as evidenced by data from experiments involving ATF3-specific siRNA, CaMKKß inhibitor, and calcium chelator, respectively. Taken together, our data suggest that HX109 might be used as a starting point for developing therapeutic agents for the treatment of BPH.


Subject(s)
Activating Transcription Factor 3/metabolism , Calcium-Calmodulin-Dependent Protein Kinase Kinase/metabolism , Plant Preparations/pharmacology , Prostatic Hyperplasia , Receptors, Androgen/metabolism , Signal Transduction/drug effects , Animals , Calcium/metabolism , Cell Line, Tumor , Humans , Male , Prostate/drug effects , Prostate/metabolism , Prostate/pathology , Prostatic Hyperplasia/chemically induced , Prostatic Hyperplasia/metabolism , Protective Agents/pharmacology , Rats , Rats, Sprague-Dawley , Testosterone Propionate/adverse effects
10.
Molecules ; 23(10)2018 Oct 14.
Article in English | MEDLINE | ID: mdl-30322186

ABSTRACT

Benign prostatic hyperplasia (BPH), an age-dependent disorder with a prevalence percentage of 60% in the 60s, has been found to involve an androgenic hormone imbalance that causes confusion between cell apoptosis and proliferation. Because general medications for BPH treatment have undesirable side effects, the development of effective alternative medicines has been considered. HBX-5 is a newly developed formula with the aim of improving BPH, and is composed of nine medicinal herbs. BPH was induced in the rats by intramuscular injection of testosterone propionate after castration. Rats were divided into six groups, and the efficacy of HBX-5 on testosterone-induced BPH in rats was estimated. In addition, RWPE-1 and WPMY-1 cells were used to demonstrate the effect of HBX-5 on BPH in vitro model. Compared with the control group, HBX-5 administration group suppressed BPH manifestations, such as excessive development of prostate, and increase of serum dihydrotestosterone and 5α-reductase concentrations. Furthermore, immunohistochemistry analysis revealed that HBX-5 significantly decreased the expression of androgen receptor (AR) and proliferating cell nuclear antigen (PCNA). In addition, results of RWPE-1 and WPMY-1 cells showed that HBX-5 inhibited the over-expression of AR and PSA in DHT-induced prostate hyperplastic microenvironments.


Subject(s)
Plant Extracts/administration & dosage , Plants, Medicinal/chemistry , Prostatic Hyperplasia/drug therapy , Testosterone Propionate/adverse effects , 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/blood , Animals , Cell Line , Dihydrotestosterone/blood , Disease Models, Animal , Disease Progression , Gene Expression Regulation/drug effects , Humans , Injections, Intramuscular , Male , Plant Extracts/pharmacology , Proliferating Cell Nuclear Antigen/metabolism , Prostatic Hyperplasia/blood , Prostatic Hyperplasia/chemically induced , Rats , Receptors, Androgen/metabolism
11.
J Endocrinol ; 237(2): 193-205, 2018 05.
Article in English | MEDLINE | ID: mdl-29563235

ABSTRACT

The purpose of present study was to infer the potential effects of testosterone increase in some male-based childhood-onset neuropsychiatric disorders, such as Tourette syndrome. Thus, the influence of early postnatal androgen exposure upon the neurobehaviors and its possible neural basis were investigated in the study. Male pup rats received consecutive 14-day testosterone propionate (TP) subcutaneous injection from postnatal day (PND) 7. The TP treatment produced the hyperactive motor behavior and grooming behavior as well as the increased levels of dopamine, tyrosine hydroxylase and dopamine transporter in the mesodopaminergic system and the elevated levels of serotonin in the nucleus accumbens, without affecting the levels of glutamate, γ-aminobutyric acid, norepinephrine and histamine in the caudate putamen and nucleus accumbens of PND21 and PND49 rats. Dopamine D2 receptor antagonist haloperidol was administered to the early postnatal TP-exposed PND21 and PND49 male rats 30 min prior to open field test. Haloperidol significantly ameliorated the motor behavioral and grooming behavioral defects induced by early postnatal TP exposure. The results demonstrated that early postnatal androgen exposure significantly disturbed the brain activity of developing male rats via enhancing the mesodopaminergic activity. It was suggested that abnormal increments of testosterone levels during the early postnatal development might be a potential risk factor for the incidence of some male-based childhood-onset neuropsychiatric disorders by affecting the mesodopaminergic system.


Subject(s)
Behavior, Animal/drug effects , Growth and Development/drug effects , Haloperidol/pharmacology , Neurodevelopmental Disorders/chemically induced , Neurodevelopmental Disorders/prevention & control , Testosterone Propionate/adverse effects , Animals , Animals, Newborn , Female , Male , Motor Activity/drug effects , Neurodevelopmental Disorders/pathology , Neurodevelopmental Disorders/physiopathology , Pregnancy , Rats , Rats, Wistar
12.
Biomed Pharmacother ; 89: 438-446, 2017 May.
Article in English | MEDLINE | ID: mdl-28249244

ABSTRACT

White wax (WW) has been traditionally used to treat hair loss in China. However there has been no reporter WW and its extract responsible for hair growth-promoting effect on androgenetic alopecia. In this paper, we examined the hair growth-promoting effects of WW and policosanol of white wax (WWP) on model animal of androgenetic alopecia and the potential target cell of WW and WWP. WW (1, 10 and 20%) and WWP (0.5, 1 and 2%) were applied topically to the backs of mice. Finasteride (2%) was applied topically as a positive control. MTS assays were performed to evaluate cell proliferation in culture human follicle dermal papilla cells (HFDPCs). The inhibition of WW and WWP for 5α- reductase were tested in Vitro. Results showed more lost hairs were clearly seen in mice treated with TP only and TP plus vehicle. Mice which received TP plus WW and WWP showed less hair loss. WW and WWP showed an outstanding hair growth-promoting activity as reflected by the follicular length, follicular density, A/T ratio, and hair bulb diameter. The optimal treatment effect was observed at 10% WW and 1% WWP, which were better than 2% finasteride treatment. MTS assay results suggested that WW and WWP remarkably increased the proliferation of HFDPCs. Inhibitor assay of 5α- reductase showed that WW and WWP inhibited significantly the conversion of testosterone to dihydrotesterone, and the IC50 values of WW and WWP were higher than that of finasteride. In Conclusion, WW and WWP could act against testosterone-induced alopecia in mice, and they promoted hair growth by inhibiting 5α-reductase activity and HFDPCs proliferation. DPCs is the target cell of WW and WWP.


Subject(s)
Alopecia/prevention & control , Fatty Alcohols/pharmacology , Hair/growth & development , Testosterone Propionate/adverse effects , Waxes/pharmacology , 5-alpha Reductase Inhibitors/pharmacology , Animals , Fatty Alcohols/chemistry , Finasteride/pharmacology , Hair Follicle , Male , Mice , Plant Extracts/pharmacology , Random Allocation , Testosterone Propionate/administration & dosage , Waxes/chemistry
13.
PLoS One ; 10(7): e0132113, 2015.
Article in English | MEDLINE | ID: mdl-26148093

ABSTRACT

Increased maternal androgen exposure during pregnancy programmes a polycystic ovary syndrome (PCOS)-like condition, with metabolic dysfunction, in adult female offspring. Other in utero exposures associated with the development of insulin resistance, such as intrauterine growth restriction and exposure to prenatal glucocorticoids, are associated with altered fetal gluconeogenesis. We therefore aimed to assess the effect of maternal androgenisation on the expression of PEPCK and G6PC in the ovine fetus. Pregnant Scottish Greyface sheep were treated with twice weekly testosterone propionate (TP; 100mg) or vehicle control from day 62 to day 102 of gestation. At day 90 and day 112 fetal plasma and liver and kidney tissue was collected for analysis. PEPCK and G6PC expression were analysed by quantitative RT-PCR, immunohistochemistry and western blotting. PEPCK and G6PC were localised to fetal hepatocytes but maternal androgens had no effect on female or male fetuses. PEPCK and G6PC were also localised to the renal tubules and renal PEPCK (P<0.01) and G6PC (P = 0.057) were lower in females after prenatal androgenisation with no change in male fetuses. These tissue and sex specific observations could not be explained by alterations in fetal insulin or cortisol. The sexual dimorphism may be related to the increase in circulating estrogen (P<0.01) and testosterone (P<0.001) in females but not males. The tissue specific effects may be related to the increased expression of ESR1 (P<0.01) and AR (P<0.05) in the kidney when compared to the fetal liver. After discontinuation of maternal androgenisation female fetal kidney PEPCK expression normalised. These data further highlight the fetal and sexual dimorphic effects of maternal androgenisation, an antecedent to adult disease and the plasticity of fetal development.


Subject(s)
Androgens/adverse effects , Gluconeogenesis/drug effects , Kidney/embryology , Polycystic Ovary Syndrome/embryology , Prenatal Exposure Delayed Effects/metabolism , Testosterone Propionate/adverse effects , Androgens/pharmacology , Animals , Disease Models, Animal , Female , Gene Expression Regulation, Developmental/drug effects , Gene Expression Regulation, Enzymologic/drug effects , Glucose-6-Phosphatase/biosynthesis , Hepatocytes/metabolism , Humans , Kidney/pathology , Male , Phosphoenolpyruvate Carboxykinase (ATP)/biosynthesis , Polycystic Ovary Syndrome/chemically induced , Polycystic Ovary Syndrome/pathology , Pregnancy , Prenatal Exposure Delayed Effects/chemically induced , Prenatal Exposure Delayed Effects/pathology , Sheep , Testosterone Propionate/pharmacology
14.
J Toxicol Environ Health A ; 78(7): 453-65, 2015.
Article in English | MEDLINE | ID: mdl-25785559

ABSTRACT

Benign prostatic hyperplasia (BPH), a disease occurring frequently among elderly males, is a slow progressive enlargement of the fibromuscular and epithelial structures of the prostate gland. Dietary factors may influence the prostate and exert an influence on prostatic growth and disease. The current study was undertaken to investigate the protective effect of dietary flaxseed supplementation against testosterone-induced prostatic hyperplasia in male rats. Forty male Wistar rats were divided into 5 groups: (1) untreated control; (2) treatment with testosterone propionate (TP) to induce prostate enlargement; (3) TP-treated group fed a diet containing 5% milled flaxseed; (4) TP-treated group fed a diet containing 10% milled flaxseed; and (5) TP-treated group fed a diet containing 20 ppm finasteride. Treatment with TP significantly increased the absolute and relative weights of different prostatic lobes, serum testosterone (T), and testosterone/estradiol ratio, as well as prostatic vascular endothelial growth factor (VEGF) expression, RNA synthesis per cell, and epithelial cell proliferation, detected as Ki67 labeling. Histopathological examination did not reveal marked differences in acinar morphology in ventral prostate, whereas morphometric analysis showed significantly increased epithelial cell height. Co-administration of flaxseed or finasteride with TP significantly reduced prostatic VEFG, epithelial cell proliferation, and RNA/DNA ratio, along with a significant increase in serum T and testosterone/estradiol ratio compared with TP-only-treated rats. Our results indicate that flaxseed, similar to the 5α-reductase inhibitor finasteride, blocked TP-induced prostate enlargement in a rat model of BPH, likely through suppression of prostatic VEFG and cellular proliferation.


Subject(s)
Cell Proliferation/drug effects , Flax/chemistry , Phytotherapy , Plant Preparations/pharmacology , Prostatic Hyperplasia/drug therapy , Animals , Disease Models, Animal , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Estradiol/blood , Male , Organ Size/drug effects , Prostate/drug effects , Prostate/metabolism , Rats , Rats, Wistar , Testosterone Propionate/adverse effects , Testosterone Propionate/blood , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism
16.
17.
Rev Neurol ; 56(6): 327-31, 2013 Mar 16.
Article in Spanish | MEDLINE | ID: mdl-23483467

ABSTRACT

INTRODUCTION. Anabolic-androgenic steroids are synthetic substances derived from testosterone that are employed for their trophic effect on muscle tissue, among other uses. Their consumption can give trigger a series of adverse side effects on the body, including the suppression of the hypothalamus-pituitary-gonadal axis as well as liver, psychiatric and cardiovascular disorders. The most common effects are altered fat profiles and blood pressure values, cardiac remodelling, arrhythmias or myocardial infarcts. CASE REPORT. We report the case of a young male, with a background of anabolic-androgenic steroids abuse, who visited because of an acute neurological focus in the right hemisphere related with an ischaemic stroke. The aetiological study, including cardiac monitoring, echocardiograph and imaging studies (magnetic resonance and arteriography) and lab findings (thrombophilia, serology, autoimmunity, tumour markers) showed no alterations. CONCLUSIONS. The association between consumption of anabolic-androgenic steroids and cardiovascular pathologies is known, but its relation with cerebrovascular disease has not received so much attention from researchers.


Subject(s)
Anabolic Agents/adverse effects , Doping in Sports , Infarction, Middle Cerebral Artery/chemically induced , Steroids/adverse effects , Substance-Related Disorders/complications , Adult , Alcoholism/complications , Brain Ischemia/chemically induced , Cerebral Angiography , Clenbuterol/adverse effects , Fibrinolytic Agents/therapeutic use , Humans , Infarction, Middle Cerebral Artery/diagnostic imaging , Infarction, Middle Cerebral Artery/drug therapy , Infarction, Middle Cerebral Artery/therapy , Male , Martial Arts , Mechanical Thrombolysis , Naltrexone/therapeutic use , Nandrolone/adverse effects , Nandrolone/analogs & derivatives , Nandrolone Decanoate , Stanozolol/adverse effects , Substance-Related Disorders/drug therapy , Testosterone Propionate/adverse effects , Tissue Plasminogen Activator/therapeutic use , Tomography, X-Ray Computed
18.
Reproduction ; 143(1): 21-33, 2012 Jan 01.
Article in English | MEDLINE | ID: mdl-22016380

ABSTRACT

We investigated the effects of different windows of testosterone propionate (TP) treatment during foetal and neonatal life in female rats to determine whether and when excess androgen exposure would cause disruption of adult reproductive function. Animals were killed prepubertally at d25 and as adults at d90. Plasma samples were taken for hormone analysis and ovaries serial sectioned for morphometric analyses. In prepubertal animals, only foetal+postnatal and late postnatal TP resulted in increased body weights, and an increase in transitory, but reduced antral follicle numbers without affecting total follicle populations. Treatment with TP during both foetal+postnatal life resulted in the development of streak ovaries with activated follicles containing oocytes that only progressed to a small antral (smA) stage and inactive uteri. TP exposure during foetal or late postnatal life had no effect upon adult reproductive function or the total follicle population, although there was a reduction in the primordial follicle pool. In contrast, TP treatment during full postnatal life (d1-25) resulted in anovulation in adults (d90). These animals were heavier, had a greater ovarian stromal compartment, no differences in follicle thecal cell area, but reduced numbers of anti-Mullerian hormone-positive smA follicles when compared with controls. Significantly reduced uterine weights lead reduced follicle oestradiol production. These results support the concept that androgen programming of adult female reproductive function occurs only during specific time windows in foetal and neonatal life with implications for the development of polycystic ovary syndrome in women.


Subject(s)
Ovary/drug effects , Ovary/physiology , Testosterone Propionate/administration & dosage , Testosterone Propionate/adverse effects , Age Factors , Animals , Animals, Newborn , Disease Models, Animal , Female , Fetus/drug effects , Humans , Ovary/abnormalities , Polycystic Ovary Syndrome/etiology , Pregnancy , Prenatal Exposure Delayed Effects , Rats , Rats, Wistar , Weight Gain/drug effects
19.
Phytomedicine ; 15(9): 722-7, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18242969

ABSTRACT

A crude polysaccharide fraction of Urtica fissa roots and stems (UFP) was obtained by water extraction and ultrafiltration, and its effect on castrated rat prostate hyperplasia induced by testosterone propionate was evaluated by the volume index, wet and dry weight index and histopathological tests. Results showed that the crude polysaccharide fraction significantly inhibited prostatic hyperplasia in animal models at doses of 62.5, 125, 250 mg/kg body wt. (administered orally). Treatment with UFP at 62.5 mg/kg body wt. decreased the volume index by 32%, the wet weight index by 17% and the dry weight index by 23%, respectively. In the high-dose group (UFP at 250 mg/kg body wt.), the indexes of volume, wet weight and dry weight decreased further by 37%, 25% and 33%, respectively. Histopathological examination showed that proliferation of prostatic epithelial cells and fibrotic tissues were significantly inhibited.


Subject(s)
Orchiectomy , Plant Extracts/pharmacology , Polysaccharides/pharmacology , Prostatic Hyperplasia/chemically induced , Prostatic Hyperplasia/prevention & control , Testosterone Propionate/adverse effects , Urticaceae/chemistry , Animals , Chromatography, Gel , Chromatography, Thin Layer , Male , Plant Extracts/isolation & purification , Polysaccharides/isolation & purification , Rats , Rats, Wistar
20.
Br J Sports Med ; 39(5): e27, 2005 May.
Article in English | MEDLINE | ID: mdl-15849280

ABSTRACT

Anabolic androgenic steroids (AAS) are used illicitly at high doses by bodybuilders. The misuse of these drugs is associated with serious adverse effects to the liver, including cellular adenomas and adenocarcinomas. We report two very different cases of adult male bodybuilders who developed hepatocellular adenomas following AAS abuse. The first patient was asymptomatic but had two large liver lesions which were detected by ultrasound studies after routine medical examination. The second patient was admitted to our hospital with acute renal failure and ultrasound (US) studies showed mild hepatomegaly with several very close hyperecogenic nodules in liver, concordant with adenomas at first diagnosis. In both cases the patients have evolved favourably and the tumours have shown a tendency to regress after the withdrawal of AAS. The cases presented here are rare but may well be suggestive of the natural course of AAS induced hepatocellular adenomas. In conclusion, sportsmen taking AAS should be considered as a group at risk of developing hepatic sex hormone related tumours. Consequently, they should be carefully and periodically monitored with US studies. In any case, despite the size of the tumours detected in these two cases, the possibility of spontaneous tumour regression must also be taken in account.


Subject(s)
Adenoma, Liver Cell/chemically induced , Anabolic Agents/adverse effects , Liver Neoplasms/chemically induced , Methenolone/analogs & derivatives , Nandrolone/analogs & derivatives , Substance-Related Disorders/complications , Testosterone Propionate/analogs & derivatives , Testosterone/analogs & derivatives , Weight Lifting , Adenoma, Liver Cell/diagnostic imaging , Administration, Oral , Adult , Anabolic Agents/administration & dosage , Biopsy, Fine-Needle/methods , Humans , Liver Neoplasms/diagnostic imaging , Magnetic Resonance Imaging/methods , Male , Methenolone/administration & dosage , Methenolone/adverse effects , Nandrolone/administration & dosage , Nandrolone/adverse effects , Nandrolone Decanoate , Oxymetholone/administration & dosage , Oxymetholone/adverse effects , Stanozolol/administration & dosage , Stanozolol/adverse effects , Substance Abuse, Intravenous , Testosterone/administration & dosage , Testosterone/adverse effects , Testosterone Propionate/administration & dosage , Testosterone Propionate/adverse effects , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...